Comparing 8 mg versus 16 mg of dexamethasone as coadjuvant treatment for acute post-operative pain: A randomized controlled clinical trial

Dulce Mª Rascón-Martínez¹, Jennifer Olúa-Estrada¹, Antonio Castellanos-Olivares¹ and Orlando Carrillo-Torres²*

¹Departamento de Anestesiología, Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Médico Nacional, Siglo XXI, Instituto Mexicano del Seguro Social; ²Departamento de Anestesiología, Hospital General de México “Dr. Eduardo Liceaga”. Mexico City, Mexico

Abstract

Background: Glucocorticoids (IEA) have an analgesic effect by suppressing the release of inflammatory mediators that induce hyperalgesia, such as tumor necrosis factor-alpha, interleukin 8, and interleukin 6. Objectives: The objectives of this study were to compare two dosages of dexamethasone (DXM) (8 vs. 16 mg) as coadjuvant in the management of acute post-operative pain in patients undergoing ear, nose, and throat surgery. Materials and Methods: We included 80 patients in a double-blind clinical trial, divided into three groups that compared two different dosages of DXM with a control group that did not receive DXM, although all groups received intravenous (IV) analgesics. The post-operative pain report was assessed using a numeric rating scale, a post-operative pain visual analog scale (VAS), and recovery time 24-h after surgery. Descriptive statistics were used to apply the Chi-square test and ANOVA test for numerical variables. Results: Pain in Group 2 compared to Group 1 and Group 3 was less during recovery, after 1 h, and 24 h with p < 0.05 as with the post-operative pain VAS, p < 0.05. Opioid consumption was similar in the three groups. Conclusions: DXM 16 mg + Metamizole 1 g IV yields better analgesic effects compared to DXM 8 mg + metamizole 1 g in the immediate post-operative period and at 24 h.

Key words: Dexamethasone. Coadjuvant. Post-operative pain.
assigned to the suppressed release of inflammatory mediators that induce hyperalgesia, such as tumor necrosis factor-alpha, interleukin 8, and interleukin 6, thereby decreasing inflammation-induced pain.

Hence, pre-operative or intraoperative administration of steroids may improve the quality of analgesia. Published studies have evaluated their effects for the prevention of post-operative pain, with additional short-term benefits, such as the prevention of post-operative nausea and vomiting even at low doses.

A meta-analysis conducted by De Oliveira et al. reported that the administration of a simple dose of dexamethasone (DXM) in the post-operative period improves the analgesic effect.

Persistent incisional pain (for more than 3 months) is common, especially after surgeries, in which bleeding is > 500 ml, in bone deformities and/or wounds > 5 cm in the skin which suggests that effective perioperative analgesia can help prevent the conversion of acute pain to chronic pain. However, the potential effect of steroids on persistent incisional pain remains unknown.

Poor management of acute post-operative pain is not free from risks or complications such as alveolar hypoventilation responsible for atelectasis, ileus, post-operative nausea, and vomiting, among others. Moreover, the likelihood of post-operative pain become chronic pain remains latent.

There are several analgesic schemes for post-operative pain treatment. Most schemes described for a successful management are based on the combination of two or more drugs. The apparent interaction between the mechanisms of the action of non-SAIDs (NSAIDs) and SAIDs suggests that combined therapies can be beneficial in inflammation and pain control, if a single dose is administered to avoid the onset and progression of the inflammation cascade through phospholipase pathway.

Conversely, the potential risk of administering steroids in the perioperative period is far from trivial, as infection of the surgical site remains a frequent and serious complication.

DXM is one of the steroids that has been established with an analgesic effect, deemed one of the most versatile SAIDs, being also used in the prophylaxis and treatment of nausea and vomiting, during the post-operative period as well as secondary to chemotherapy. Furthermore, it has been successfully used in the reduction of edema and post-operative stridor.

Ear, nose, and throat (ENT) surgeries carry a high risk of post-operative nausea and vomiting associated with significant pain after surgery. Three different types of pain have been identified: incisional, visceral, and shoulder pain. Local infiltration anesthesia (Ropivacaine, Lidocaine, or Bupivacaine), together with the use of steroids, has been effective in controlling pain after this type of surgical intervention.

One of the proposed drugs for the administration of multimodal analgesia is DXM. However, more studies are necessary to establish the risk-benefit ratio for its use.

Several studies have recommended a dose of 5-8 mg IV of DXM mainly to reduce post-operative nausea and vomiting. However, as an analgesic in combination with drugs belonging to the NSAID group, its risk benefit in reducing pain and convalescence of patients after undergoing ENT surgery has not yet been assessed.

As DXM is widely used in the transoperative period of patients, this study aims to assess whether 16 mg of DXM is a better analgesic dosage than 8 mg for acute post-operative pain in patients undergoing ENT surgery.

Materials and methods

Study framework and participants

The study was approved by the Ethics and Research Committees of Hospital de Especialidades del Centro Medico Nacional Siglo XXI del Instituto Mexicano del Seguro Social with Registration Number 2014-3601-81 and Dr. Dulce María Rascón Martínez was assigned as principal investigator. Subjects were recruited at the same hospital and were invited to participate in the research during the pre-anesthetic visit the day before the surgery. Patients were scheduled for surgery corresponding to the otorhinolaryngology subspecialty under general anesthesia. Patients classified as the American Society of Anesthesiologists (ASA) I, II, and III were included, according to the standards and guidelines of the ASA. Exclusion criteria included patients with contraindications and/or allergic to DXM or metamizole, diabetic patients (glucocorticoids trigger glycemic decontrol in these patients), and surgeries >6 h (as the antiemetic effect of DXM will not be at its peak), in addition to patients that due to the complexity of the surgery or decision of the anesthesiologist in charge of the procedure, were admitted to different protocols than the one proposed for acute post-operative pain management.

Study design and procedures

We conducted a prospective, longitudinal, controlled, double-blind, and randomized clinical trial. Assignment
to each group was based on a random number table. An independent researcher received a numbered and sealed envelope that informed the name of the drug to be prepared. The medication was administered 30 min before the surgical incision as follows: Group 1; 8 mg of DXM were given in 10 ml saline and the subsequent administration of metamizole established at 15 mg/kg and Group 2; DXM 16 mg plus metamizole under the same administration method as Group 1. To patients in Group 3, they were administered a placebo that consisted only of 10 ml of 0.9% saline plus the subsequent administration of metamizole as in the other groups.

As a safety measure, baseline glucose levels were recorded between the groups by monitoring arterial blood gas (ABG) 2 h after the end of the surgical procedure. Each group was evaluated for pain, anxiolytic dosages, as well as opioid consumption during surgery.

**Statistical analysis**

Subjects who reported pain improvement after the use of DXM were the main variable used to calculate the sample size. A meta-analysis was used as reference, in which a difference in medians (MD) of −0.49.38 was reported. Thus, by assuming $\alpha$ level of 0.05 and a $\beta$ power of 80% for a two-tailed test, at least 31 patients were required per treatment group. We chose to add nine (10%) patients to the sample, considering that some of them could not finish the study.

The description of demographic and clinical variables was performed using frequencies and percentages for categorical variables and with means and standard deviations (±) for continuous variables.

**Results**

Ultimately, 102 patients were included in the trial. Twenty-two patients were excluded for the following reasons: five patients withdrew their consent; in nine cases, surgery was suspended by the service due to causes unrelated to the study; in six cases, an analgesic scheme different from the one proposed in the study was used; and finally, two patients showed increased blood sugar levels before surgery. In all surgeries, patients underwent inpatient care (no ambulatory surgery).

The average age was 52 ± 1.74 years of age, with $p = 0.137$. Of the total sample analyzed, 62.5% ($n = 50$) corresponded to the female gender and 37.5% ($n = 30$) to the male gender. About 98.8% of patients ($n = 79$) were classified as ASA 2 and 1.2% ($n = 1$) as ASA 3. All patients underwent ENT surgery, the distribution of surgeries is shown in Fig. 1.

**Pain assessment**

To perform the statistical analysis of pain behavior, normality tests were conducted initially to determine if it was possible to analyze the groups by means of an ANOVA test, the variables that had a normal distribution obtained $p > 0.05$.

Numeric rating scale measurements were made on admission to the post-anesthesia care unit (PACU) and 24 h after discharge from the operating theater. Detailed data distribution between the groups is shown in table 1, which contains the pain report, according to the self-reported visual analog scale (VAS) of post-operative pain applied at 24 h (Table 1).

The differences between the groups are shown in Figs. 2-5.

Regarding opioid consumption used during the surgical procedure, 302.00 ± 42 mcg of fentanyl were used for Group 1; 311.11 ± 64 mcg were used for Group 2; and 317.86 ± 43 mcg for Group 3. With an average consumption of 310.66 ± 50 mg for all groups, no statistically significant differences were found for this variable, with $p = 0.530$.

Likewise, we quantified the amount of anxiolytics used. The need for administration of anxiolytics during the anesthetic procedure was only necessary in approximately 30% of participants of each group: seven patients in Groups 1 and 2 and eight patients in the control group. The average administration of anxiolytics for all groups resulted in 0.30 mg ± 0.5 ($p = 0.762$).

**Glycemia**

In an additional analysis, a glycemic index measurement was carried out, considering the baseline values obtained by the pre-operative blood chemistry and ABG control approximately 2 h after the end of the surgical procedure. This control was performed only in half of the patients (15 patients in Group 1, 11 patients in Group 2, and 13 patients in the control group). Because no clinically relevant increases in the glycemic index of the first 40 cases were observed during the study, and as the sampling method for blood sugar level measurement is deemed invasive, the researchers decided to suspend these measurements. The mean pre-operative glycemic index between the groups was 106.62 ± 25 ($p = 0.224$) mg/dl and the post-operative mean was
116.08 ± 31 mg/dl with no statistically significant differences (p = 0.999).

Discussion

In our study, the use of DXM during the transoperative period proved to be beneficial for pain control, due to the behavior of the pain reports of post-operative patients from ENT surgery.

Pain scores in this type of surgery were reported as mild or nonexistent, as only Grades 1-3 were reported and patients did not require rescue analgesics in the post-operative period, which is reflected in the same self-reported VAS of post-operative pain. The patients who were administered DXM mostly reported a VAS score < 2. Therefore, we can infer that the surgeries were not associated with greater intensity pain.
The pain during the PACU stay was considerably lower as well as at discharge and at the first 24 h after surgery. The effect of the opioid used during the surgery was discarded, as no significant differences were observed in its consumption between the groups. The graphs show that these pain reports have a better performance when a dose of 16 mg DXM was used in the measurements. A potential explanation is that the inflammatory response to surgical injury of the tissues is largely responsible for the pain intensity in the post-operative period\(^4\) and the glucocorticoid inhibits the phospholipase peripherally, affecting cyclooxygenase and lipoxygenase pathways\(^5\).

In our study, we decided to perform a blood glucose measurement 2 h after the surgical procedure, without detecting any significant increased levels. It is worth noting that the blood glucose levels were measured 2 h after surgery, without detecting any significant increased levels.

Table 1. Pain report of the analyzed groups

| Numeric rating scale | Dexamethasone group 8 mg | Dexamethasone group 16 mg | Control group | p value |
|----------------------|--------------------------|---------------------------|---------------|---------|
| PACU (X ±SD)         | 1.24±1.01                | 0.93±0.99                 | 1.61±0.91     | 0.040   |
| CI 95%               | 0.82-1.66                | 0.53-1.32                 | 1.25-1.96     |         |
| 1 H (X ±SD)          | 1.68±1.03                | 1.04±1.05                 | 2.18±0.98     | 0.000   |
| CI 95%               | 1.26-2.10                | 0.62-1.45                 | 1.80-2.56     |         |
| 24 H (X ±SD)         | 1.32±0.96                | 1.01-1.24                 | 2.36±1.19     | 0.000   |
| CI 95%               | 1.12-1.92                | 0.51-1.49                 | 1.89-2.82     |         |
| VAS                  |                          |                           |               |         |
| 24 H (X ±SD)         | 1.56±0.71                | 1.41±0.57                 | 2.29±0.85     | 0.000   |
| CI 95%               | 1.27-1.85                | 1.18-1.63                 | 1.95-2.62     |         |

SD: standard deviation; CI: confident interval; PACU: post-anesthesia care unit; VAS: visual analog scale.

Figure 4. Pain assessment with verbal numeric scale 24 h after surgery using one-way ANOVA – p < 0.05, analysis between groups on post hoc tests: Tukey.

Figure 5. Assessment with the self-reported visual analog scale of post-operative pain 24 h after surgery using one-way ANOVA – p < 0.05, analysis between groups on post hoc tests: Tukey.
considering that after the administration of DXM, maximum blood glucose levels occur between 8 and 10 h, so measurement times could explain this result. However, we think that the inclusion of non-diabetic patients and the use of a single dose of the steroid have no clinically relevant alterations in the glycemic index. Due to the study design, this finding cannot be asserted and more in-depth studies will be required for better methodological design of this aspect and with measurements up to 12 h after the administration of DXM to detect maximum glycemic values.

Multiple studies suggest that intermediate doses of corticosteroids, such as DXM, seem to be the safest and most effective option of multimodal analgesia. It also shows that analgesia is greater when steroids are administered preoperatively (at least 1 h before surgery) or during the induction of anesthesia5,10,15,22. Hence, post-operative pain treatment with a multimodal technique that includes DXM as a coadjuvant, decreases pain scores and the use of rescue analgesia during the first 24 h of the immediate post-operative period15,16,22,37.

The results of our study were no exception.

Systematic reviews have been performed where it can be concluded that a single perioperative intravenous (IV) dose of DXM had small but statistically significant analgesic benefits37; thus, more clinical trials are necessary for in-depth information on this topic, mainly in surgeries where much higher pain scores are expected.

Conclusions

The administration regimen of 16 mg of DXM + 1 g of Metamizole IV reduces immediate post-operative pain, up to the first 24 h, without increasing blood glucose levels of healthy patients undergoing ENT surgery.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References

1. Udelsman R, Holbrook NJ. Endocrine and molecular responses to surgical stress. Curr Probl Surg. 1994;31:608-720.
2. Kool BA, Deuchman CS. The inflammatory response to surgery and trauma. Curr Opin Crit Care. 2006;12:325-32.
3. Sessler DI, Ben-Eliyahu S, Maciaj EJ, Parat MO, Buggy DJ. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp Clin Trials. 2006;29:517-26.
4. Bagry H, de la Cuadra Fontaine JC, Asenso JF, Bracco D, Carl F. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. Reg Anesth Pain Med. 2008;33:17-23.
5. Buvanendran A, Koon JS, Berger RA, Hallab NJ, Saha C, Negrescu E, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006;104:403-10.
6. Rudolph JL, Ramlawi B, Kuchel GA, McElhaney JE, Xie D, Sellick FW, et al. Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Sci Med Sci. 2008;63:184-9.
7. Anselmi A, Possati G, Gaudio MD. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg. 2009;88:326-33.
8. Lunn TH, Kristensen BB, Andersen LO, Husted H, Otte KS, Gaarm-Larsen L, et al. Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial. Br J Anaesth. 2011;106:230-8.
9. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anest Analg. 2005;101:55-92.
10. Sapsokly RM, Romero LM, Munck AC. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endor Rev. 2000;21:35-89.
11. Hargreaves KM, Costello A. Glucocorticoids suppress levels of immuno-reactive bradykinin in inflamed tissue as evaluated by microdialysis probes. Clin Pharmacol Ther. 1990;48:168-78.
12. Serralla A, Bueno L, Ledó J, Sanhuaja A, García R, Arnal C, Martínez P, et al. Evaluación del dolor postoperatorio en la colecistectomía laparoscópica bajo anestesia-analgésia multimodal en régimen ambulatorio. Rev Esp Anestesiol Reanim. 2002;49:461-7.
13. Czock D, Keiller F, Rasche FM, Häusler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
14. Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain. 1993;55:171-81.
15. Schurr UP, Zünd G, Horerstrup SP, Grünenfelder J, Maly FE, Vogt PR, et al. Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass. Annu Thorac Surg. 2001;72:1316-20.
16. De Oliveira GS Jr., Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011;115:575-88.
17. Apfel CC, Kortilia K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441-51.
18. Wildgaard K, Ravj J, Kehlet H. Chronic post-thoracotomy pain: a critical review of pathogenic mechanisms and strategies for prevention. Eur J Cardiothorac Surg. 2009;36:170-80.
19. Brandsborg B, Nikolajsen L, Hansen CT, Kehlet H, Jensen TS. Risk factors for chronic pain after hysterectomy: a nationwide questionnaire and database study. Anesthesiology. 2007;106:1003-12.
20. Gärnert R, Jensen MB, Nielsen J, Ewertz M, Kromann H, Kehlet H, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985-92.
21. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000;93:1123-33.
22. Joshi GP, Ogummake BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin North Am. 2005;23:21-36.
23. Bergboge BO, Akinwande JA, Adeyemo WL, Ladeinde AL, Arotiba GT, Ogurinewe MO, et al. Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery. Head Face Med. 2005;11:1.
25. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg. 2000;90:186-94.

26. Park SH, Han SH, Do SH, Kim JW, Rhee KY, Kim JH, et al. Prophylactic dexamethasone decreases the incidence of sore throat and hoarseness after tracheal extubation with a double-lumen endobronchial tube. Anesth Analg. 2008;107:1814-8.

27. Koç S, Memis D, Sut N. The preoperative use of gabapentin, dexamethasone, and their combination in varicocele surgery: a randomized controlled trial. Anesth Analg. 2007;105:1137-42.

28. Movafegh A, Soroush AR, Navi A, Sadegui M, Esfehani F, Akbarian-Tefaghi N. The effect of intravenous administration of dexamethasone on postoperative pain, nausea and vomiting after intrathecal injection of meperidine. Pain Med. 2007;104:1115-20.

29. Hval K, Thagaard KS, Schlichting E, Reader J. The prolonged postoperative analgesic effect when dexamethasone is added to a nonsteroidal antiinflammatory drug (rofecoxib) before breast surgery. Pain Med. 2007;105:1234-40.

30. Moore PA, Star P, Smiga ER, Costello BJ. Preemptive rofecoxib and dexamethasone for prevention of pain and trismus following third molar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:E1-7.

31. Kardash K, Sarrazin F, Tessler M, Velly A. Single-dose dexamethasone reduces dynamic pain after total hip arthroplasty. Pain Med. 2008;106:1122-7.

32. Aminmansour B, Khalili HA, Ahmadi J, Novian M. Effect of high-dose intravenous dexamethasone on postlumbar discectomy pain. Spine (Phila Pa 1976). 2006;31:2415-7.

33. Stewart R, Bill R, Ullah R, McConaghy P, Hall SJ. Dexamethasone reduces pain after tonsillectomy in adults. Clin Otolaryngol Allied Sci. 2002;27:321-6.

34. Bigat Z, Boztug N, Hadimioglu N, Cete N, Coskunfirat N, Ertok E, et al. Does dexamethasone improve the quality of intravenous regional anesthesia and analgesia? A randomized, controlled clinical study. Anesth Analg. 2006;102:605-9.

35. Turan A, Sessler DI. Steroids to ameliorate postoperative pain. Anesthesiology. 2011;115:457-9.

36. Cortés VR, Alfaro L, Espinoza MA, Gómez C, López GA, Plata EJ. Diagnóstico Y Tratamiento De Colecistitis Y Colelitiasis. Guía De Práctica Clínica. Catálogo Maestro De Guías De Práctica Clínica. IMSS-237-09; 2009.

37. Waldron NH, Jones CA, Gan TJ, Allen TK, Habib AS. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth. 2013;110:191-200.